Three different molecular tests have been validated as providing useful data that can help a man and his doctors to come to decisions about the management and treatment of localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Decipher, genetic, genomic, molecular, Oncotype, PROLARIS, test | 2 Comments »
A relatively brief, current, full-text review article by Loeb and Ross is available on the Medscape web site and discusses the three currently available tests for assessment of genomic risk for men with localized forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Decipher, genome, Oncotype, prognosis, PROLARIS, test | 6 Comments »
The Intergroupe Coopérateur Francophone de Recherche en Onco-urologie (ICFuro) has just published a review of the available evidence on the clinical validity and utility of six prognostic biomarkers available for the assessment of prostate cancer-related risk. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 4Kscore, Decipher, GPS, MiPS, Oncotype, phi, prognosis, PROLARIS, review, test | 4 Comments »
A paper given at the recent annual meeting of the American Society for Radiation Ocology (ASTRO) suggests that the Decipher genomic classifier may help to distinguish between treatment options for men in need of salvage radiation therapy after first-line radical prostatectomy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen, classifier, Decipher, deprivation, genomic, radiation, salvage | 1 Comment »
A decision that tortures patients with adverse findings (positive margins, and/or stage T3/4) after prostatectomy is whether to jump into adjuvant radiation right away, or wait until PSA rises to 0.2 ng/ml before having salvage radiation. … READ M\ORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, classifier, Decipher, genomic, progression, radiation, risk, salvage | 7 Comments »
Both Myriad Genetics and Genome DX Biosciences issued media releases today stating that Medicare contractors have issued draft coverage recommendations for tests used to assess the aggressiveness of prostate cancer based on genetic/genomic analyses of tissue from biopsy and post-surgical samples. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biomarker, Decipher, genetic, genomic, PROLARIS, risk, test | Leave a comment »
An article just published on the Medscape web site addresses data on the potential of GenomeDx Bioscence’s new “Decipher” test which “could” (according to one urologic oncologist) help prevent over-treatment of at least some men with prostate cancer. One might ask whether we can — as yet — decipher the value of the Decipher test. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Decipher, expression, gene, risk, Treatment | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 